KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Weighted Average and Diluted) (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at $3.34 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 10.6% year-over-year to $3.34; the TTM value through Dec 2025 reached -$2.1, down 124.53%, while the annual FY2025 figure was -$5.84, 167.51% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $3.34 in Q4 2025 per JAZZ's latest filing, up from -$11.74 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.34 in Q4 2025 and bottomed at -$11.74 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.16, with a median of $0.8 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 3366.67% in 2023, then plummeted 571.49% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.64 in 2021, then tumbled by 500.0% to -$3.84 in 2022, then surged by 137.24% to $1.43 in 2023, then soared by 111.19% to $3.02 in 2024, then grew by 10.6% to $3.34 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $3.34 in Q4 2025, -$11.74 in Q2 2025, and $3.02 in Q4 2024.